Figure 7

Working model of SH2-U-box.
The chimeric ubiquitin ligase SH2-U-box is able to interact with BCR-ABL and BCR-ABL T315I, promoting their ubiquitination and subsequent degradation. As a result, SH2-U-box attenuates BCR-ABL-dependent pathway, inhibits the proliferation and induces the apoptosis of imatinib- sensitive and resistant CML cells.